AbbVieโs medical aesthetics division Allergan may not getย the makeover it was counting on this year if the Federal Trade Commission (FTC) has anything to say about it.
The FTC has asked Allergan to submit additional information about its plan to buyย devicemaker Soliton, according toย documentsย Soliton filed with the Securities and Exchange Commission (SEC) on Aug.ย 6. The so-called โsecond requestโ indicates the FTC is launching a deeper probe than its standard review of merger proposals, sparked by potential antitrust concerns.